Replies to post #16419 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Any thoughts on which other one might have been dropped from Mylan partnership?

Reviewing each one listed, I cannot haphazard a guess. However, I did decifer that MNTA has the PATENTED expertise to make interchangeables anywhere/anyhow. Here's a "cursory" list from the following branded drugs - as stated:

METHODS OF EVALUATING AND MAKING BIOLOGICS

In one embodiment, the target biologic is selected from the products marketed as:

Humira®, Avastin®; Rituxan®; Mabthera®; Campath®; Herceptin®; Xolair®; Prolia®;

Vectibix®; ReoPro®; Zenapax®; Simulect®; Synagis®; Remicade®; Mylotarg®; Campath®; Raptiva®; Zevalin®; Erbitux®; Tysabri®; Lucentis®; Soliris®; Cimzia®; Ilaris®; Arzerra®; Bexxar®; Simponi®; Prolia®; Xgeva®; Actemra®; Benlysta®; Adcetris®; Yervoy®.

https://worldwide.espacenet.com/publicationDetails/description?CC=WO&NR=2013181576A2&KC=A2&FT=D&ND=3&date=20131205&DB=EPODOC&locale=en_EP

They've hit the MOTHERLODE here!! Is this a takeover, or what?!

[DewDiligence]

[Referring to #msg-128079578]: If you take out 2 & 3 (Avastin & Humira)… You have five potential candidates for the Mylan partnership - Orencia is not listed there so there is one extra.

The MNTA-MYL partnership is for six FoBs—i.e. Orencia plus five others. So I do not understand what you mean about an “extra” entry in the names listed in #msg-128079578.